Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esophagogastric Junction or Gastric Cancer after failure of one but not more than two prior lines of systemic therapy

Trial Profile

Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, Esophagogastric Junction or Gastric Cancer after failure of one but not more than two prior lines of systemic therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elisidepsin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms IMAGE
  • Most Recent Events

    • 04 Apr 2022 This trial has been completed in France (End Date: 04 May 2021), according to European Clinical Trials Database record.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
    • 23 Jun 2012 Planned number of patients changed from 118 to 126 as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top